TYK Medicines, Inc (2410.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$3.11 (+1.80%) as of
Key statistics
- Market cap
- 1.18B
- Forward P/E
- -5.89
- EPS (TTM)
- -0.640
- Dividend yield
- 0.00%
- 52-week range
- 2.410 – 15.760
- Beta
- -0.41
- Profit margin
- 0.00%
- Volume
- 207.50k
About TYK Medicines, Inc
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors. In addition, it develops TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; CDK4, preclinical-stage oral CDK4 inhibitor for cancer treatment; TY-3002, a small-molecule, orally administered glucagon like peptide-1 receptor agonist (GLP-1RA) intended for the treatment of type 2 diabetes mellitus (T2DM) and obesity; and EGFR/FAK (PROTAC) and PI3Ka to treat solid tumors; and GLP-1 for the treatment of T2DM and overweight or obesity. The company has a collaboration agreement with Qilu for development, manufacturing, and commercialization of TY-9591, a highly selective, irreversible EGFR-TKI self-developed by TYK Medicines to reduce the formation of toxic metabolites. The company was incorporated in 2017 and is headquartered in Huzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Huzhou, China
- Employees
- 184
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.